T Smith – BNN Bloomberg Hot Picks
Terry Smith, Director of Life Sciences Research at Emerald Advisers, joins BNN Bloomberg to share his Hot Picks in biotech.
In-House Research Orientation
10-Step Repeatable Process
Skill Set of Research Analysts
Team Approach to Rapidly Changing Sectors
24 Years Average Industry Experience
Longevity of Research Team
Always True to Growth and Cap Size Mandates
LFSC Disclosures
Investing involves risk. Principal loss is possible. The Fund focuses its investments in securities of companies that are categorized in the “life sciences” sector, including companies in the pharmaceutical, biotechnology, health care services, and medical device industries. Because of this, companies in the Fund’s portfolio may share common characteristics and may be more sensitive to changes in government funding or subsidies, new or anticipated legislative changes, or technological advances.
To the extent the Fund focuses on the health care sector, the Fund may be more susceptible to the particular risks that may affect companies in the health care sector than if it were invested in a wider variety of companies in unrelated sectors. Cyber security risk is the risk of an unauthorized breach and access to Fund assets, Fund or customer data (including private shareholder information), or proprietary information, or the risk of an incident occurring that causes the Fund, the investment adviser, custodian, transfer agent, distributor and other service providers and financial intermediaries to suffer data breaches, data corruption or lose operational functionality or prevent Fund investors from purchasing, redeeming or exchanging shares or receiving distributions.
Investments in securities of micro- and small-capitalization companies may be more vulnerable to adverse issuer, market, political, or economic developments than securities of larger-capitalization companies. The Fund invests in the securities of foreign companies. Investing in securities of foreign companies involves risks generally not associated with investments in the securities of U.S. companies, including the risks associated with fluctuations in foreign currency exchange rates, less stringent investor protections, unreliable and untimely information about issuers, and political and economic instability.
ETFs are subject to additional risks that do not apply to conventional mutual funds, including the risks that the market price of an ETF's shares may trade at a premium or discount to its net asset value, an active secondary trading market may not develop or be maintained, or trading may be halted by the exchange in which they trade, which may impact an ETF's ability to sell its shares. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. Brokerage commissions will reduce returns.
Fund holdings are subject to change at any time and should not be considered recommendations to buy or sell any security. Please click here for current holdings.
Visit emeraldetfs.com/lfsc/prospectus for the F/m Emerald Life Sciences Innovation ETF Prospectus.
The F/m Emerald Life Sciences Innovation ETF is distributed by Quasar Distributors, LLC.
SPIT Disclosures:
Investing involves risk. Principal loss is possible. An investor should consider the investment objectives, risks, and charges and expenses of the fund carefully before investing. A prospectus, which contains this and other information about the fund, may be obtained by calling 1-800-617-0004/visiting www.emeraldetfs.com. The prospectus should be read carefully before investing.
The Fund may invest in companies listed on U.S. and Canadian exchanges that are engaged in the use of, or have exposure to, DLT and blockchain. The risks associated with DLT, including blockchain, may not be fully known at this time, including securities fraud, theft, loss, or destruction. Use of DLT and blockchain may also result in lost or delayed transactions.
Cyber Security Risk. Cyber security risk is the risk of an unauthorized breach and access to Acquiring Fund assets, Acquiring Fund or customer information, proprietary information, or operating systems.
Financial Technology Risk. The Acquiring Fund may invest in companies engaged in financial technology-related activities. Companies that are developing financial technologies to disrupt existing or displace established financial institutions generally face competition from much larger and more established firms.
Special Situations Risk. The Acquiring Fund will seek to benefit from Special Situations, such as mergers, reorganizations, or other unusual events that may create an opportunity for investment. Investments in Special Situations may not produce the intended results and can result in significant losses for the Acquiring Fund. A Special Situation may have a negative impact on the price of the issuer’s securities and fail to produce gains or produce a loss for the Acquiring Fund.
The Acquiring Fund may have exposure to securities in emerging markets. Emerging Markets are defined by the Advisors as countries that are generally considered to be emerging or developing by the World Bank, the International Finance Corporation, the International Monetary Fund, or the United Nations. Emerging market securities tend to be more volatile than securities in developed countries. Issuers in emerging markets are also subject to risks not typically associated with issuers in more developed countries. Growth stocks are typically priced higher than other stocks, in relation to earnings and other measures, because investors believe they have more growth potential.
The Acquiring Fund may invest in companies listed on foreign markets. Securities markets are generally less liquid than securities in the United States, and foreign companies may be more vulnerable to adverse issuer, market, political, or economic developments than securities of U.S. companies and governments. Investments in private placements could decrease the Acquiring Fund’s liquidity and/or prevent the Acquiring Fund from disposing of such securities at a fair price. Investments in private placements also decrease the marketability of the securities. Equity securities of companies and funds involved in Initial Public Offerings (“IPOs”) are subject to less diverse risks. IPOs involve special risks because they are less liquid and more volatile than established companies. The Acquiring Fund may invest in stocks, rights, warrants, and other securities of special purpose acquisition companies or entities with a purpose entities (collectively, “SPACs”). SPACs are often subject to extreme price volatility and speculative trading. The Acquiring Fund may also invest in distressed companies, which may not produce the intended results and may result in significant losses.
The Acquiring Fund is subject to additional risks that do not apply to conventional mutual funds, including the risks that the market price of an ETF’s shares may trade at a discount to its net asset value (“NAV”), or that an actively secondary trading market may not develop or be maintained, and that trading may be halted by the exchange on which the ETF shares are traded. Brokerage commissions will reduce returns. Shares of any ETF can be bought and sold at market price (not NAV) and are not individually redeemed from the ETF. Brokerage commissions will reduce returns.
Distributed by Quasar Distributors, LLC.
He has published several research articles in leading journals in the fields of oncology and dermatology and, at the 2004 Annual AACR Conference, Dr. Trivedi was the recipient of an award from the American Association for Cancer Research and AFLAC for his research efforts on melanoma. While at Penn State College of Medicine, he received the Rite Aid Graduate Fellowship Award in Pharmacology. Dr. Trivedi received both a PhD and an MBA from Pennsylvania State University. He completed his medical internship in 1999 and received his medical degree (MBBS) from Bombay University, India.
Dr. Smith is a Director – Life Sciences Research for Emerald Advisers and a Portfolio Manager of the F/m Emerald Life Sciences Innovation ETF. He spent the Summer/Fall of 2005 as an Intern at Emerald before joining the firm in the Fall of 2006.
Dr. Smith received his PhD in Integrative Biosciences – Molecular Toxicology at Penn State College of Medicine, in Fall 2006. He has co-authored several research abstracts and articles on ‘the molecular signaling pathways involved in hormone induced cholesterol metabolism’ for the Journal of Investigative Dermatology, as well as for the Society for Investigative Dermatology’s annual international meetings. He received his MBA from the Pennsylvania State University (2004), where he also was inducted into the Beta Gamma Sigma National Business Honor Society. Dr. Smith received his BS degree in Biology (with a minor in Chemistry) from Messiah College in 2000.
Ms. Sears is Senior Vice President and a senior member of the Small Cap Portfolio Management team. She is also a Portfolio Manager of the Emerald Growth Fund and the F/m Emerald Life Sciences Innovation ETF.
She works directly with the research team, interacting with team members across economic sectors and helping guide the day-to-day portfolio management decision-making process.
Ms. Sears is also responsible for portfolio risk monitoring, portfolio attribution analysis, as well as Emerald’s portfolio management-related client communications. From a research perspective, Ms. Sears maintains research coverage of the Retail, Apparel, Restaurant, Consumer Goods and Consumer Technology companies.
She has been quoted in Fortune, Money, the Dow Jones News Service and various regional newspapers. Ms. Sears received a BS in Business Administration from Millersville University and an MBA from Villanova University.
Portfolio Manager, Emerald Financial Services Private Equity Fund I, LP.; past Trustee and Vice President of the Emerald Mutual Funds; Chief Investment Officer, PA State Employees’ Retirement System (1985-1992); Member, CFA Institute; past Member, Pennsylvania State University Research Foundation; past Trustee, Evangelical Lutheran Church in America Board of Pensions; past Trustee, Pennsylvania State University Endowment Council (1998-2004); and past Chair, President, & Director of Central Pennsylvania Investment Managers. He was formerly Chairman of the Diakon Board and Chairman of the Diakon Lutheran Fund, its endowment arm. Mr. Mertz has been quoted in The Wall Street Journal and in USA Today and has served as speaker at various investment seminars and programs across the country. He has been a guest on CNBC’s Mutual Fund Investor and has been interviewed several times on CNBC and Bloomberg TV. Mr. Mertz graduated from Millersville University with a BA in Economics. Mr. Mertz is a CFA charterholder.
Kenneth G. Mertz has earned the right to use the Chartered Financial Analyst designation. CFA Institute marks are trademarks owned by the CFA Institute.
Mr. Garner is Director of Research and a member of the Small Cap Growth Portfolio Management team. He is also a Portfolio Manager of the Emerald Growth Fund and the F/m Emerald Life Sciences Innovation ETF. Mr. Garner’s research efforts are primarily focused on small and mid-sized firms in the Consumer Discretionary, Consumer Staples, Industrials, and Technology sectors.
He has appeared on Bloomberg Television and CNBC. He also has been quoted in Fortune, Bloomberg Business News, USA Today, Dow Jones News Service, Standard & Poor’s, MarketWatch, Investor’s Business Daily, Wall Street Journal, and other media. Mr. Garner previously served as President of the Millersville University Foundation and Chair of the Investment Committee. He currently serves on the Advisory Council for the Lombardo College of Business at Millersville University. Prior to joining Emerald in 1994, Mr. Garner was the Program Manager of the PA Economic Development Financing Authority (PEDFA) and an Economic Development Analyst with the PA Department of Commerce’s Office of Technology Development. Mr. Garner received an MBA from the Katz Graduate School of Business, University of Pittsburgh, and graduated magna cum laude with a BA in Economics from Millersville University.